December 04th, 2024 – M | O | C Cancer Care has achieved a groundbreaking milestone in oncology by successfully discharging its first patient who underwent CAR-T cell therapy for Relapsed Refractory Diffuse Large B-Cell Lymphoma (DLBCL), a type of hematological cancer. This accomplishment places M | O | C among the pioneering community cancer care institutions in India to offer this advanced and life-saving therapy.
The patient, a 60-year-old resident of Thane, was admitted on November 5, 2024, after battling relapsed and refractory lymphoma for over three years. Previous treatments, including immunotherapy, had been unsuccessful. Following CAR-T therapy, the patient experienced no complications and was successfully discharged on November 24, 2024.
What Is CAR-T Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary advancement in cancer treatment. It involves genetically modifying a patient’s own T-cells to precisely target and destroy cancer cells. By harnessing the immune system’s power, CAR-T therapy provides new hope to patients with aggressive and previously untreatable blood cancers.
This achievement was made possible with the help of ImmunoACT, whose expertise in CAR-T cell manufacturing enabled the delivery of this transformative therap.
A Breakthrough in Oncology Care
This milestone underscores M | O | C’s commitment to pioneering advanced therapies and delivering world-class cancer care. “CAR-T therapy is particularly significant for patients with relapsed and refractory lymphomas, who have limited options after the failure of conventional treatments,” said Dr. Suraj Chiraniya.
Dr. Suraj Chiraniya and Dr. Ashray Kole, Hemato-Oncologists and BMT Specialists at M | O | C, added, “This breakthrough marks the beginning of a new era in oncology care, bringing renewed hope to countless patients and families battling complex blood cancers.”
About M | O | C Cancer Care & Research Centre
M | O | C is a chain of community cancer centers operating in Western India. Equipped with state-of-the-art facilities and an expert team of oncologists, M | O | C leads the way in offering innovative treatments, including CAR-T therapy, to improve patient outcomes.
Key Highlights of the CAR-T Success Story
• Patient Details: 60-year-old male from Thane, Mumbai
• Condition: Relapsed Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
• Treatment Timeline: Admitted on November 5, 2024; discharged on November 24, 2024
• Background: Failed three prior treatment regimens, including immunotherapy
• Outcome: Achieved successful remission post-CAR-T therapy
Looking Ahead
This achievement solidifies Mumbai’s position as a hub for advanced oncology care. M | O | C is proud to lead the way in bringing innovative cancer treatments to private healthcare settings, offering new hope to patients and their families.